BlueBird Bio Wounded After Roth Downgrade

bluebird bio Inc BLUE shares are trading lower by $2.00 at $76.65 in Monday's session.

Its four-day rally from its January 31 low ($67.10) to as high as $78.80 in Friday's session before closing at $78.65 has been interrupted by a Roth Capital downgrade. Before the open, the firm downgraded the issue from Buy to Neutral.

In a see-saw session, the issue has found support just ahead of Friday's low ($75.15), only reaching $75.40. On the upside, the issue hasn't been able reach its closing price from Friday ($78.65) as $77.75 stands a the current high for the session. That was the highest close for the issue since December 6, when it ended that session at $78.95.

The company won't Q4 earnings until February 22. Street estimates for EPS are $(1.86) on revenues of a paltry $1.76 million.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesTechnicalsIntraday UpdateAnalyst RatingsMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!